How long you can live with squamous cell carcinoma depends heavily on where it occurs and how early it’s caught. A small skin squamous cell carcinoma found early has a 5-year survival rate above 90%, while squamous cell carcinoma of the lung or head and neck that has spread to distant organs drops to around 8%. The single biggest factor in your outlook is stage at diagnosis.
Skin SCC: The Most Common and Most Curable
Cutaneous (skin) squamous cell carcinoma is the type most people are asking about, and it carries the best prognosis by far. When caught early and treated with surgery, the 5-year disease-specific survival is roughly 96%. Even among tumors classified as high-risk, 5- and 10-year progression-free survival rates from metastatic disease are about 93% and 90%, respectively. In practical terms, most people with skin SCC are cured and live a normal lifespan.
That said, skin SCC is not a single disease. A shallow, small tumor on the forearm behaves nothing like a deep, aggressive tumor on the ear or scalp. Tumor size and depth are the details that matter most. Tumors wider than 2 centimeters double the risk of recurrence and triple the rate of spread. Depth of invasion beyond 2 millimeters increases the risk of local recurrence tenfold, and invasion into the fat layer beneath the skin raises the metastasis risk elevenfold. Tumors less than 2 millimeters deep rarely spread at all.
How Stage Affects Survival
SEER data from the National Cancer Institute, covering cases diagnosed between 2015 and 2022, shows a stark difference in survival depending on how far the cancer has spread at the time of diagnosis. These numbers include squamous cell carcinomas across all body sites, not just skin:
- Localized (confined to the original site): 49.5% five-year relative survival
- Regional (spread to nearby lymph nodes or tissue): 28.8%
- Distant (spread to far-off organs): 8.0%
These all-site numbers look lower than the skin-only figures because they include lung, head and neck, esophageal, and cervical squamous cell carcinomas, which are diagnosed at later stages and carry worse prognoses. If your diagnosis is specifically cutaneous SCC that hasn’t spread, your odds are significantly better than these combined figures suggest.
SCC of the Head, Neck, and Oral Cavity
Squamous cell carcinoma in the head and neck region sits between skin SCC and lung SCC in terms of seriousness. Oral SCC, for example, shows 5-year survival rates of about 62% for stage I and 80% for stage II, but those numbers fall sharply with advancing disease: 42% for stage III and 19% for stage IV. Patients with large lymph node involvement (classified as N3 disease) have a 5-year overall survival of approximately 30%, regardless of which treatment they receive.
For head and neck SCC that develops a single distant metastasis, the 5-year survival is about 35%. But if multiple metastases appear, that drops to just 4%. This is one area where targeted treatment of isolated metastases can make a meaningful difference, with patients receiving that approach showing a 5-year survival of around 31%.
Lung SCC
Squamous cell carcinoma of the lung is the second most common form of non-small-cell lung cancer, making up about 25% of cases. It is strongly linked to cigarette smoking. The overall 5-year survival for non-small-cell lung cancer is approximately 15%, largely because 60 to 70% of patients already have advanced disease by the time they’re diagnosed. Early-stage lung SCC that’s surgically removable has much better outcomes, but it’s frequently found too late for that to be an option.
What Happens When SCC Comes Back
Recurrence changes the picture. Among patients with recurrent head and neck skin SCC, the 5-year disease-free survival drops to about 47%, and roughly 40% of those patients go on to develop a second recurrence. Most of those second recurrences happen locally, at or near the original site. The most dangerous scenario is distant metastasis at the time of recurrence: in one study, no patient with distant spread at recurrence survived beyond 13 months.
Patients whose recurrent SCC has spread to lymph nodes have a 2-year disease-free survival of about 48%, compared to 73% for those without lymph node involvement. The takeaway is that recurrence itself isn’t necessarily a death sentence, but each recurrence narrows the margin of safety.
Immunosuppression Raises the Risk
If you’ve had an organ transplant and take anti-rejection medications, your squamous cell carcinoma behaves differently than in the general population. These tumors grow faster, tend to be larger at diagnosis, and are more likely to invade deeply or spread along nerves. The risk of metastasis within two years of removing a skin SCC is about 7% in transplant recipients, compared to roughly 2% in people with normal immune function.
For transplant patients whose SCC does metastasize, the 3-year survival is about 56% and the 5-year survival is 34%. Death rates from metastatic SCC in this group range from 13% to 46% over two to four years, depending on how widespread the disease becomes. If you’re on long-term immunosuppression, more frequent skin checks and earlier treatment of any suspicious spots can meaningfully improve your odds.
How Immunotherapy Is Improving Outcomes
For high-risk skin SCC, a newer class of treatment called immune checkpoint inhibitors has changed the landscape. The FDA approved cemiplimab as an after-surgery treatment for patients whose skin SCC has a high chance of returning. In a clinical trial of 415 patients, those who received the drug after surgery and radiation had a 12% rate of disease progression or death over about five years of follow-up, compared to 32% for those who received a placebo. That translates to a 68% reduction in the risk of the cancer coming back.
This treatment works by releasing the brakes on your immune system’s T cells, allowing them to recognize and attack cancer cells that were previously hiding. It’s given as an injection over the course of up to 48 weeks. It’s not for every patient with skin SCC, but for those with high-risk features like deep invasion, nerve involvement, or incomplete surgical margins, it represents a substantial improvement in long-term cancer control.
Tumor Features That Predict Your Outlook
Beyond stage, several specific characteristics of the tumor itself influence how long you can live with SCC. For skin SCC in particular, the key factors are:
- Size: Tumors under 2 centimeters carry a low risk. Above that threshold, recurrence risk doubles and metastasis risk triples.
- Depth: Tumors under 2 millimeters deep have virtually no metastatic risk. Between 2 and 4 millimeters, the metastasis rate is about 17%. Over 4 millimeters, it jumps to 83%.
- Location: SCC on the ears, lips, and temples carries higher risk than SCC on the trunk or extremities.
- Nerve involvement: Tumors that grow along nerves (perineural invasion) are more likely to recur and spread.
- Immune status: Chronic immunosuppression from transplant drugs, blood cancers, or other conditions worsens outcomes at every stage.
With early and appropriate treatment, the vast majority of skin squamous cell carcinomas are curable. The cases that become life-threatening are typically those that were neglected, are located in high-risk areas, grew deeply before detection, or occur in people whose immune systems are compromised. For SCC at other body sites, the calculus shifts: early detection remains critical, but the baseline risks are higher and the path to cure is more complex.